Zydus Cadila gets USFDA nod to market motion sickness tablets

Zydus Cadila on Wednesday announced that the company has received an approval from United States Food and Drug Administration (USFDA) to market Meclizine Hydrochloride tablets. 

Meclizine Hydrochloride tablets (US RLD: AntivertTM tablets) in the strengths of 12.5 mg and 25 mg is used to treat symptoms of motion sickness like nausea, vomiting and dizziness. It could also ease the dizziness and loss of balance (vertigo) due to inner ear problem. The manufacturing of the drug will take place at the group’s manufacturing facility at SEZ, Ahmedabad.

Zydus Cadila is a global pharmaceutical company with a huge range of healthcare therapies. It has a strong global presence in the markets of United States, France and Spain as well as in high profile markets of South Africa and Latin America. It has 292 approvals and has filed over 390 abbreviated new drug applications (ANDAs) since the financial year 2003-04.

Cadila Heathcare Limited has a 52-week high of Rs 383.65 and 52-week low of Rs 206.45. The stock is trading at Rs 365.60 with a decline of 0.37 per cent at 2.43 pm with an intraday high of Rs 373.35 on BSE.